ArticleBMC cardiovascular disorders2026
Veno-arterial ECMO in fulminant myocarditis: a retrospective single-center case series.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionFulminant myocarditis (FM) is a life-threatening condition that may require veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Evidence from Latin America remains limited.
methodsWe conducted a retrospective case series of adult patients with FM requiring VA-ECMO support at a high-complexity center. Clinical, hemodynamic, metabolic, and echocardiographic variables were analyzed descriptively.
resultsThis case series included 16 patients with a mean age of 39.03 years (SD 12.93), with an equal number of male and female patients. Twenty-eight-day survival was 68.75% (11/16). According to the Charlson Comorbidity Index, 70% (11/16) of the patients had a score of 0. The median survival after veno-arterial ECMO (SAVE) score was 1.5 (interquartile range [IQR] 1-3). Lactate levels and vasoactive-inotropic score (VIS) reduced from 3.79 (IQR: 1.68-8.46) mmoL/L and 68 (IQR: 54-113) pre-ECMO to 1.52 (IQR: 1.26-2.03) mmoL/L and 20 (IQR: 13-45) post-ECMO, respectively. In contrast, PaO₂/FiO₂ ratio, left ventricular ejection fraction, and fractional area change (FAC) increased from 186 (IQR: 126-245) mmHg, 16.5% (IQR: 10%-34%), and 29.5% (IQR: 19-33) pre-ECMO to 260 (IQR: 178-307) mmHg, 51.5% (IQR: 45%-55%), and 42% (IQR: 37-45) post-ECMO, respectively. Complications included renal events in 56.25% (9/16), bleeding 37.5% (6/16), cardiovascular complications in 31.25% (5/16) and infectious complications in 33.33% (5/16) of the participants.
conclusionsIn this cohort of patients with FM supported with VA-ECMO, changes in hemodynamic, metabolic, and echocardiographic parameters were observed following support initiation, with survival rates comparable to prior reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.